This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pierre-Paul, D. Articles by Gahtan, V. Search for Related Content PubMed PubMed Citation Articles by Pierre-Paul, D. Articles by Gahtan, V. Social Bookmarking                         What's this?

Noncholesterol-Lowering Effects of Statins

Yale University School of Medicine, Section of Vascular Surgery, New Haven, CT

Vivian Gahtan, MD

Yale University School of Medicine, Section of Vascular Surgery, P.O. Box 208062, FMB 137, 333 Cedar Street, New Haven, CT 06520 Vivian.gahtan{at}yale.edu

Statins, 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, inhibit the rate-limiting enzyme in cholesterol synthesis and lead to a significant reduction of plasma lipid concentrations. As a clear correlation exists between serum cholesterol and cardiovascular risk, statins have become increasingly important in current preventive medicine. Studies prompted by the extraordinary benefits afforded by these drugs have reported minimal changes in the vasculature of hypercholesterolemic patients when compared with clinical benefits and have led to further investigations to determine the underlying reasons for these clinical benefits. The purpose of this review is to present the wide array of systems that HMGCoA reductase inhibitors are known to influence, which range from adverse events due to coronary artery disease, stroke risk, platelet function, endothelial function, and inflammatory effects to intracellular signaling pathways that control vascular cell migration, proliferation, and differentiation.

Vascular and Endovascular Surgery, Vol. 37, No. 5, 301-313 (2003)
DOI: 10.1177/153857440303700501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Kones The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 309 - 315. [Abstract] [PDF]

				V. M. Campese and J. Park HMG-CoA Reductase Inhibitors and Renal Function Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1100 - 1103. [Full Text] [PDF]

				M. Sugita, H. Sugita, and M. Kaneki Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1390 - 1395. [Abstract] [Full Text] [PDF]

				N. D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Renal Physiol, February 1, 2006; 290(2): F262 - F272. [Abstract] [Full Text] [PDF]

				V. M. Campese, M. K. Nadim, and M. Epstein Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17. [Abstract] [Full Text] [PDF]